Irisin Expression and Gene Polymorphism in Type II Diabetic Patients With and Without CAD

Serum Irisin Level & FDNC5 Genetic Polymorphism Can Predict the Presence &Severity of Coronary Artery Disease in Patients With Type II DM?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04957823

Acronym

CAD

Enrollment

100

Registered

2021-07-12

Start date

2021-04-20

Completion date

2023-10-30

Last updated

2024-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irisin Gene Polymorphism in Type II Diabetic Patients

Brief summary

This is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism and the presence and severity of coronary artery disease in patients with Type II DM.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Inclusion criteria

* This study will include type II diabetic patients aged between 18 and 45 years old

Exclusion criteria

1. Recent acute myocardial infarction. 2. patients with Heart Failure 3. Active infection 4. End stage renal failure (GFR \< 30 ml/min) or on dialysis 5. Liver cell failure 6. Athletes or having heavy muscular exercise in the previous 3 days

Design outcomes

Primary

Measure	Time frame	Description
Irisin level	6 months	detect the serum level of irisin hormone by ELIZA in nanogram/decilitre(ng/dl)
FNDC5 Genotyping	6 months	whether homogenetic or heterogenetic

Countries

Egypt

Outcome results